A Giustina, G Arnaldi, F Bogazzi, S Cannavò, A Colao, L De Marinis, E De Menis, E Degli Uberti, F Giorgino, S Grottoli, A G Lania, P Maffei, R Pivonello, E Ghigo
BACKGROUND: In 2007, we published an opinion document to review the role of pegvisomant (PEG) in the treatment of acromegaly. Since then, new evidence emerged on the biochemical and clinical effects of PEG and on its long-term efficacy and safety. AIM: We here reviewed the emerging aspects of the use of PEG in clinical practice in the light of the most recent literature. RESULTS: The clinical use of PEG is still suboptimal, considering that it remains the most powerful tool to control IGF-I in acromegaly allowing to obtain, with a pharmacological treatment, the most important clinical effects in terms of signs and symptoms, quality of life and comorbidities...
June 2017: Journal of Endocrinological Investigation